NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Alembic Pharma Receives USFDA Tentative Approval for Larotrectinib; Sole First-to-File Status
Alembic Pharmaceuticals has received tentative USFDA approval for Larotrectinib Capsules (25 mg and 100 mg), used for treating solid tumors. The company is the sole first applicant to file a Paragraph IV certification, which may grant it 180 days of generic marketing exclusivity in the U.S. upon final approval. The market size for this product is estimated at US$ 91 million for the twelve months ending March 2026. This milestone brings Alembic's total USFDA approvals to 241, including 20 tentative approvals.
முக்கிய அம்சங்கள்
Received USFDA tentative approval for Larotrectinib Capsules (25 mg and 100 mg), a generic version of Vitrakvi.Identified as the sole first applicant with a Paragraph IV certification, potentially securing 180 days of exclusivity.Target market size for the product is approximately US$ 91 million as of March 2026.Cumulative USFDA ANDA approvals reached 241, consisting of 221 final and 20 tentative approvals.
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition from tentative to final approval, as the sole first-to-file status provides a significant competitive advantage and high-margin potential during the 180-day exclusivity period.
Alembic Pharma to Acquire 45% Stake in New Canadian JV for Market Expansion
Alembic Pharmaceuticals has executed a Shareholders' Agreement to invest in a newly incorporated Canadian entity, 17989377 Canada Inc. The company will hold a 45% equity stake, partnering with Difgen Holdings LLC (45%) to establish a platform for pharmaceutical commercialization in Canada. This move aims to strengthen Alembic's presence in the North American market through localized development, distribution, and marketing. Following the investment, the Canadian corporation will be classified as an associate company of Alembic.
முக்கிய அம்சங்கள்
Acquisition of a 45% equity stake in the newly formed 17989377 Canada Inc.Joint venture partnership with Difgen Holdings LLC (45%) and other parties (10%).Strategic focus on development, marketing, and distribution of pharma products specifically for the Canadian market.The Canadian entity will become an Associate company of Alembic Pharmaceuticals post-investment.Governance structure includes nominee directors from shareholders and an independent director.
👀 கவனிக்க வேண்டியவை
This is a positive strategic step for geographic diversification; investors should track the joint venture's operational milestones and its eventual impact on the company's international revenue growth.
Alembic Pharma Receives USFDA Final Approval for Haloperidol Tablets; Market Size $27M
Alembic Pharmaceuticals has received final USFDA approval for its Haloperidol Tablets (1 mg, 2 mg, 5 mg, 10 mg, and 20 mg), a generic equivalent to Haldol. The drug is indicated for managing psychotic disorders and Tourette’s Disorder in both children and adults. The addressable market for this product is estimated at US$ 27 million for the twelve months ending March 2026. This approval further strengthens Alembic's US generics portfolio, bringing their total cumulative USFDA approvals to 240.
முக்கிய அம்சங்கள்
Final USFDA approval received for Haloperidol Tablets in five different strengths (1 mg to 20 mg).Product is therapeutically equivalent to the reference listed drug Haldol by Ortho McNeil Pharmaceutical.Estimated market size for the product is US$ 27 million for the 12-month period ending March 2026.Alembic now has a cumulative total of 240 ANDA approvals, including 221 final and 19 tentative approvals.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to gain market share in this $27 million segment. While the market size is relatively small, the consistent pace of USFDA approvals reinforces Alembic's strong R&D and regulatory execution capabilities.
Alembic Pharma Appoints Tushar Mehta as Head-R&D (API); 24+ Years Experience
Alembic Pharmaceuticals has appointed Mr. Tushar Mehta as Head-R&D (API) effective June 3, 2026. Mr. Mehta brings over 24 years of specialized experience in API R&D, having previously led 100+ development programs with 45+ successful commercializations. His expertise spans complex therapeutic areas including oncology and antivirals, and he has a proven track record of managing large teams of up to 200 scientists. This strategic hire is aimed at strengthening the company's technical leadership and regulatory filing capabilities in the API segment.
முக்கிய அம்சங்கள்
Mr. Tushar Mehta appointed as Head-R&D (API) and Senior Management Personnel effective June 3, 2026.Brings 24+ years of experience, having led 100+ API development programs and commercialized over 45.Expertise includes handling complex APIs like oncology, Remdesivir, and Molnupiravir, plus FDA/EMA regulatory filings.Previously served as SVP & Head – R&D (API) at Cadila Pharmaceuticals and held leadership roles at Piramal and Ami Life Sciences.Has experience directing large R&D teams of 200 scientists and filing multiple USDMFs.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development for the company's long-term API pipeline and vertical integration strategy. Monitor for an increase in USDMF filings and complex API launches in the upcoming fiscal years.
Alembic Pharma Appoints Ramesh Juneja as Senior Management Personnel for India Business
Alembic Pharmaceuticals has designated Mr. Ramesh Juneja as Senior Management Personnel effective June 1, 2026. Mr. Juneja, currently the EVP of Human Health (Sales and Marketing) for the India Business, brings over 30 years of industry experience. His background includes significant leadership roles at top-tier companies like Sun Pharma and Cipla. This move aims to leverage his expertise in driving business growth and market expansion within the competitive Indian pharmaceutical landscape.
முக்கிய அம்சங்கள்
Appointment of Mr. Ramesh Juneja as Senior Management Personnel effective June 1, 2026Over 30 years of experience in pharma sales and marketing across acute and chronic segmentsFormer leadership roles at Sun Pharmaceutical Industries, Cipla, and Reliance Retail (Netmeds)Educational background includes an MBA from Symbiosis and executive programs at ISB and NUS
👀 கவனிக்க வேண்டியவை
This appointment strengthens the domestic leadership; investors should monitor for improved execution in the India business. No immediate action is required other than tracking performance metrics.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Alembic Pharmaceuticals has received final USFDA approval for its ANDA for Levothyroxine Sodium Tablets, a generic version of AbbVie's Synthroid. The approval covers 12 different strengths ranging from 25 mcg to 300 mcg, targeting a massive market estimated at US$ 1,869 million for the 12 months ending March 2026. This approval marks a significant addition to the company's US portfolio, which now includes 220 final ANDA approvals. The drug is used for treating hypothyroidism and managing certain types of thyroid cancer.
முக்கிய அம்சங்கள்
Final USFDA approval received for Levothyroxine Sodium Tablets in 12 different dosage strengths.Target market size for the product is estimated at US$ 1,869 million annually as of March 2026.Product is therapeutically equivalent to the reference listed drug Synthroid by AbbVie, Inc.Alembic now holds a cumulative total of 239 ANDA approvals, including 220 final approvals.The medication is indicated for hypothyroidism replacement therapy and thyroid cancer management.
👀 கவனிக்க வேண்டியவை
This is a high-impact approval given the large addressable market size of nearly $1.9 billion. Investors should monitor the company's commercial launch timeline and market share gains in the US generic space.
Alembic Pharma Q4 FY26: FY PAT Grows 16% to ₹675 Cr; Targets Double-Digit Growth in FY27
Alembic Pharmaceuticals reported a steady Q4 FY26 with revenue of ₹1,838 crores, up 4% YoY, while full-year revenue grew 10%. The company achieved a full-year PAT of ₹675 crores, a 16% increase, driven by international market expansion and specialty therapies in India. Management has provided a positive outlook for FY27, targeting low double-digit top-line growth and planning R&D investments of ₹750-800 crores. Key growth drivers include the scaling of the US branded business and improved capacity utilization at the F2 and F3 facilities.
முக்கிய அம்சங்கள்
Q4 FY26 revenue rose 4% to ₹1,838 crores with core EBITDA margins improving to 25%.Full-year FY26 PAT increased 16% to ₹675 crores, supported by a 20% growth in Ex-US international markets.R&D spend for FY27 is projected at ₹750-800 crores, focusing on high-value NCE-1 and Day 1 molecules.The F3 ophthalmic line is currently at full capacity, prompting a planned expansion to meet demand.FY27 Capex is guided at ₹300-350 crores, primarily for debottlenecking and replacement activities.
👀 கவனிக்க வேண்டியவை
Investors should focus on the successful scale-up of the US branded business and the margin impact of high-value R&D filings. The company's shift toward execution-led growth and improved facility utilization provides a solid foundation for medium-term gains.
Alembic Pharma FY26 Net Profit Rises 27% to ₹640 Cr; Dividend Hiked to ₹12 Per Share
Alembic Pharmaceuticals reported a steady 10.2% growth in annual standalone revenue to ₹6,651.38 crore for FY26. The standalone net profit saw a significant 27.3% increase to ₹640.42 crore, though this was aided by a one-time deferred tax credit of ₹100.27 crore in the final quarter. Operating margins improved to 16.82% from 15.74% year-on-year, reflecting better operational efficiency despite exceptional costs. The board has rewarded shareholders by increasing the dividend to ₹12 per share, up from ₹11 in the previous year.
முக்கிய அம்சங்கள்
Annual Revenue from Operations grew 10.2% YoY to ₹6,651.38 crore.Standalone Net Profit increased by 27.3% to ₹640.42 crore for the full year.Board recommended a higher dividend of ₹12 per equity share (600% of face value).Operating margins improved to 16.82% compared to 15.74% in the previous fiscal.Exceptional items included a ₹48.64 crore impact from new Labour Codes and an ₹18.35 crore write-down for the Sikkim facility.
👀 கவனிக்க வேண்டியவை
The company shows healthy revenue growth and margin expansion, coupled with a higher dividend payout. Investors should maintain a positive outlook but monitor the impact of the new Labour Codes on future employee costs.
Alembic Pharma Passes Brazil's ANVISA GMP Inspection with Zero Observations for Karakhadi Facility
Alembic Pharmaceuticals has successfully cleared a Good Manufacturing Practices (GMP) inspection by the Brazilian Health Regulatory Agency (ANVISA) for its API-III facility at Karakhadi. The inspection, conducted from May 11 to May 15, 2026, concluded with zero observations, reflecting high compliance standards. This regulatory approval is significant as it allows the company to supply multiple Active Pharmaceutical Ingredients (APIs) to the Brazilian market. Such clearances are critical for maintaining and expanding the company's international revenue streams and reducing regulatory risk.
முக்கிய அம்சங்கள்
Successful completion of ANVISA (Brazil) GMP inspection at the Karakhadi API-III facility.The audit resulted in zero observations, indicating full compliance with regulatory standards.Inspection was conducted over a five-day period from May 11, 2026, to May 15, 2026.The clearance facilitates the export of multiple APIs to the Brazilian pharmaceutical market.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that strengthens the company's export potential in Latin America. The zero-observation report mitigates regulatory concerns and supports long-term growth in the API segment.
Alembic Pharma Q4 FY26: Net Profit Jumps 29% to Rs 203 Cr; US Revenue Grows 11%
Alembic Pharmaceuticals reported a strong bottom-line performance for Q4 FY26, with Net Profit surging 29% YoY to Rs 203 Cr despite a modest 4% growth in total revenue to Rs 1,848 Cr. The US formulation segment was a major growth driver, increasing 11% to Rs 564 Cr, supported by six new launches and a strategic entry into the US branded market with Pivya. The India branded business grew 4% to Rs 568 Cr, led by specialty segments like Gynaecology and Gastrology. Pre-R&D EBITDA margins remained healthy at 25%, reflecting disciplined cost management and operational efficiency.
முக்கிய அம்சங்கள்
Net Profit (PAT) increased 29% YoY to Rs 203 Cr for the quarter ended March 31, 2026.US Formulation revenue grew 11% to Rs 564 Cr, supported by 6 new product launches and 4 ANDA approvals.Pre-R&D EBITDA rose 8% YoY to Rs 455 Cr with a robust margin of 25%.India Branded Business revenue reached Rs 568 Cr, marking a 4% YoY growth.Strategic entry into the US Branded Pharmaceuticals market with the launch of Pivya for uUTIs.
👀 கவனிக்க வேண்டியவை
Investors should view the significant margin improvement and the strategic pivot into the US branded specialty market as positive long-term catalysts. Monitor the commercial traction of Pivya and the sustainability of the 25% pre-R&D EBITDA margins in upcoming quarters.
Alembic Pharma Receives USFDA EIR for Karakhadi Injectable Facility (F-III)
Alembic Pharmaceuticals has successfully received the Establishment Inspection Report (EIR) from the USFDA for its Injectable Facility (F-III) located at Karakhadi. This report follows a regulatory inspection conducted between February 9 and February 18, 2026. The receipt of an EIR indicates that the USFDA has concluded its audit and the facility is deemed compliant with manufacturing standards. This clearance is a significant milestone for the company's injectable portfolio and future product launches in the US market.
முக்கிய அம்சங்கள்
Received Establishment Inspection Report (EIR) from USFDA on May 13, 2026Inspection conducted at Karakhadi Injectable Facility (F-III) from Feb 9 to Feb 18, 2026Successful closure of the regulatory audit for this critical manufacturing siteClears the path for potential new product approvals from the F-III facility
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive regulatory development that reduces compliance risk for the company's injectable segment. Maintain a positive outlook on the stock as this clearance supports future revenue growth from the US market.
Alembic Pharmaceuticals has received tentative approval from the USFDA for Darolutamide Tablets, 300 mg, a generic version of Bayer's Nubeqa. The drug is indicated for treating adult patients with various forms of prostate cancer, including non-metastatic and metastatic castration-sensitive prostate cancer. This approval targets a significant market, with IQVIA estimating the annual market size at approximately US$ 3,155 million for the period ending March 2026. This milestone strengthens Alembic's oncology portfolio and brings its total USFDA ANDA approvals to 238.
முக்கிய அம்சங்கள்
Received USFDA tentative approval for Darolutamide Tablets, 300 mg, used in prostate cancer treatment.Target market size for the drug is estimated at US$ 3,155 million for the twelve months ending March 2026.The product is therapeutically equivalent to the reference listed drug Nubeqa by Bayer HealthCare Pharmaceuticals.Alembic now has a cumulative total of 238 ANDA approvals, including 219 final and 19 tentative approvals.
👀 கவனிக்க வேண்டியவை
This is a positive development for Alembic's US generic pipeline in the high-value oncology segment. Investors should monitor the transition from tentative to final approval and the subsequent commercial launch timeline.
Alembic Pharma Receives USFDA Final Approval for Fingolimod Capsules (Market Size $145M)
Alembic Pharmaceuticals has secured final USFDA approval for Fingolimod Capsules (0.5 mg), which is the generic version of Novartis' Gilenya. The drug is indicated for treating relapsing forms of multiple sclerosis in patients aged 10 and older. According to IQVIA data, the market size for this product is estimated at US$ 145 million for the twelve months ending December 2025. This approval strengthens Alembic's US portfolio, bringing their total cumulative ANDA approvals to 237.
முக்கிய அம்சங்கள்
Final USFDA approval for Fingolimod Capsules, 0.5 mg, a generic equivalent to Gilenya.Target market size estimated at US$ 145 million for the 12-month period ending December 2025.The drug is used for treating relapsing forms of multiple sclerosis (MS) in adults and children.Alembic now has a total of 237 ANDA approvals, consisting of 219 final and 18 tentative approvals.
👀 கவனிக்க வேண்டியவை
This approval is a positive development for Alembic's US generics pipeline and should contribute to revenue growth. Investors should monitor the company's execution and market share capture in this competitive $145 million segment.
Alembic Pharma Incorporates Wholly-Owned Subsidiary in Germany with EUR 25,000 Share Capital
Alembic Pharmaceuticals has announced the incorporation of a 100% wholly-owned subsidiary, Alembic Pharmaceuticals GmbH, in Germany. The new entity is established with an initial share capital of EUR 25,000, consisting of 25,000 shares at EUR 1.00 each. This strategic move is designed to explore new business opportunities and establish a direct presence for the promotion, sale, and distribution of pharmaceutical products in the German market. As a newly formed entity, it currently has nil turnover and is yet to commence commercial operations.
முக்கிய அம்சங்கள்
Incorporation of 100% wholly-owned subsidiary 'Alembic Pharmaceuticals GmbH' in Germany.Initial share capital set at EUR 25,000 divided into 25,000 shares of EUR 1.00 each.Objective is to promote, sell, and distribute pharmaceutical products in the European geography.The entity is a fresh incorporation with zero turnover as of the announcement date.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive long-term strategic move to strengthen the company's footprint in the European market. Monitor future updates regarding product registrations and revenue contributions from this new German entity.
Alembic Pharma Receives USFDA Final Approval for Methotrexate Injection
Alembic Pharmaceuticals has received final USFDA approval for its Methotrexate Injection USP, which is therapeutically equivalent to Hospira's reference drug. The injection is a folate analog metabolic inhibitor used to treat various cancers, rheumatoid arthritis, and severe psoriasis. This approval marks a significant addition to Alembic's US portfolio, targeting both oncology and autoimmune segments. With this, the company's cumulative USFDA approvals have reached 236, including 218 final approvals.
முக்கிய அம்சங்கள்
Received final USFDA approval for Methotrexate Injection USP in 50 mg/2 mL and 1g/40 mL strengthsProduct is indicated for multiple neoplastic diseases including Leukemia, Breast Cancer, and Head/Neck CancerAlso approved for treating rheumatoid arthritis and severe psoriasisCumulative USFDA approvals now stand at 236 (218 final and 18 tentative approvals)
👀 கவனிக்க வேண்டியவை
This approval strengthens Alembic's US generic pipeline in high-value therapeutic areas like oncology and immunology. Investors should monitor the company's commercial launch timeline and market share gains in these segments.
Alembic Pharma Re-appoints Pranav Amin as Managing Director for 5-Year Term
Alembic Pharmaceuticals has officially implemented the re-appointment of Mr. Pranav Amin as Managing Director, effective April 1, 2026. This follows the shareholder approval previously granted during the 15th Annual General Meeting held in August 2025. Mr. Amin, who leads the company's International Business, will serve a five-year term and is not liable to retire by rotation. The move ensures leadership continuity as the company focuses on international expansion and research-driven growth.
முக்கிய அம்சங்கள்
Mr. Pranav Amin re-appointed as Managing Director for a 5-year term starting April 1, 2026.The appointment was previously approved by shareholders at the 15th AGM on August 5, 2025.Mr. Amin is responsible for the International Business division, focusing on global R&D and manufacturing.The appointee is not liable to retire by rotation and is not debarred by any SEBI order.Mr. Amin is part of the promoter family, being the son of Chairman Chirayu Amin.
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine management continuity event that maintains the current strategic direction of the company's international operations. No immediate portfolio action is required based solely on this announcement.
Alembic Pharma: Chirayu Amin Appointed Executive Chairman for 5 Years; Steps Down as CEO
Alembic Pharmaceuticals has announced that Mr. Chirayu Amin has transitioned to the role of Executive Chairman for a five-year term starting April 1, 2026. He has simultaneously relinquished his position as the Chief Executive Officer (CEO) following the completion of his previous tenure. This move, which was approved by shareholders in August 2025, ensures leadership stability within the promoter family. Mr. Amin is the father of the company's current Managing Directors, Pranav and Shaunak Amin, indicating a clear succession and continuity plan.
முக்கிய அம்சங்கள்
Mr. Chirayu Amin appointed as Executive Chairman for a 5-year term effective April 1, 2026.Relinquished the position of Chief Executive Officer (CEO) as of March 31, 2026.The transition was previously approved by shareholders at the 15th AGM held on August 5, 2025.Mr. Amin will not be liable to retire by rotation during his new tenure as Executive Chairman.
👀 கவனிக்க வேண்டியவை
This is a planned leadership transition that ensures continuity within the promoter-led management. Investors should view this as a routine administrative update with no immediate impact on the company's operational strategy.
Alembic Pharma Receives USFDA Final Approval for Paroxetine ER Tablets (12.5 mg)
Alembic Pharmaceuticals has received final USFDA approval for its supplemental Abbreviated New Drug Application (sANDA) for Paroxetine Extended-Release Tablets, 12.5 mg. This product is therapeutically equivalent to Paxil CR Tablets and is used to treat major depressive and anxiety disorders. This approval strengthens Alembic's US portfolio, bringing its cumulative total to 235 ANDA approvals, including 216 final approvals. The approval allows the company to expand its presence in the central nervous system (CNS) therapeutic segment in the US market.
முக்கிய அம்சங்கள்
Received final USFDA approval for Paroxetine Extended-Release Tablets USP, 12.5 mgProduct is therapeutically equivalent to the reference listed drug Paxil CR Tablets (Apotex Inc.)Indicated for Major depressive disorder (MDD), Panic disorder (PD), and Social anxiety disorder (SAD)Cumulative USFDA approvals now stand at 235 (216 final and 19 tentative approvals)
👀 கவனிக்க வேண்டியவை
This approval is a positive development for Alembic's US generics business. Investors should monitor the company's product launch timeline and its ability to capture market share in the competitive CNS drug category.
Alembic Pharmaceuticals Incorporates New Subsidiary in Thailand for Market Expansion
Alembic Pharmaceuticals Limited has successfully incorporated a new subsidiary, Alembic Pharmaceuticals (Thailand) Co., Ltd., in Thailand. The company holds a 99.99% stake in the new entity, which has an initial share capital of 3,000,000 Baht. This strategic move is designed to explore new business opportunities and facilitate the promotion, sale, and distribution of pharmaceutical products within the Thai geography. While the subsidiary has yet to commence operations, it marks a clear intent to strengthen the company's international presence.
முக்கிய அம்சங்கள்
Incorporation of Alembic Pharmaceuticals (Thailand) Co., Ltd. as a 99.99% owned subsidiaryInitial share capital of 3,000,000 Baht divided into 300,000 shares of 10 Baht eachPrimary objective is to promote and distribute pharmaceutical products in the Thailand marketCurrent turnover is nil as the entity is newly incorporated and yet to start operationsInvestment is made in cash for the acquisition of share capital
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's progress in the Southeast Asian market as this expansion could provide a new revenue stream. No immediate action is required as the financial impact will only be visible once operations commence.
Alembic Pharma Reports First US Prescription Sale of Branded Antibiotic Pivya®
Alembic Pharmaceuticals has achieved its first prescription sale of Pivya® in the US, marking its official entry into the US branded specialty market. Pivya® is a first-line antibiotic for uncomplicated urinary tract infections (uUTIs), a therapeutic category with approximately 30 million prescriptions annually in the US. This launch follows a strategic acquisition and represents a shift from a purely generic-focused model to a branded specialty portfolio in the US. The company has established an initial sales footprint and plans a phased expansion of its field force to drive growth.
முக்கிய அம்சங்கள்
First prescription sale of Pivya® in the US, marking Alembic's first branded product launch in the region.Targets the uUTI market in the US, which accounts for approximately 30 million prescriptions annually.Marketed through Alembic Therapeutics LLC, a step-down wholly owned subsidiary of the company.Represents a strategic shift to build a branded specialty portfolio alongside its established generics business.Initial sales footprint established across key US territories with plans for phased field force expansion.
👀 கவனிக்க வேண்டியவை
Investors should monitor the prescription growth and market penetration of Pivya® as it represents a higher-margin opportunity compared to traditional generics. This strategic entry into the US branded market could be a long-term value driver for the stock.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
